• Something wrong with this record ?

ERG deletions in childhood acute lymphoblastic leukemia with DUX4 rearrangements are mostly polyclonal, prognostically relevant and their detection rate strongly depends on screening method sensitivity

M. Zaliova, E. Potuckova, L. Hovorkova, A. Musilova, L. Winkowska, K. Fiser, J. Stuchly, E. Mejstrikova, J. Starkova, J. Zuna, J. Stary, J. Trka,

. 2019 ; 104 (7) : 1407-1416. [pub] 20190110

Language English Country Italy

Document type Journal Article, Research Support, Non-U.S. Gov't

Grant support
NV15-30626A MZ0 CEP Register

ERG-deletions occur recurrently in acute lymphoblastic leukemia, especially in the DUX4-rearranged subtype. The ERG-deletion was shown to positively impact prognosis of patients with IKZF1-deletion and its presence precludes assignment into IKZF1plus group, a novel high-risk category on AIEOP-BFM ALL trials. We analyzed the impact of different methods on ERG-deletion detection rate, evaluated ERG-deletion as a potential marker for DUX4-rearranged leukemia, studied its associations with molecular and clinical characteristics within this leukemia subtype, and analyzed its clonality. Using single-nucleotide-polymorphism array, genomic polymerase chain reaction (PCR) and amplicon-sequencing we found ERG-deletion in 34% (16 of 47), 66% (33 of 50) and 78% (39 of 50) of DUX4-rearranged leukemia, respectively. False negativity of ERG-deletion by single-nucleotide-polymorphism array caused IKZF1plus misclassification in 5 patients. No ERG-deletion was found outside the DUX4-rearranged cases. Within DUX4-rearranged leukemia, the ERG-deletion was associated with higher total number of copy-number aberrations, and, importantly, the ERG-deletion positivity by PCR was associated with better outcome [5-year event-free survival (EFS), ERG-deletion-positive 93% vs. ERG-deletion-negative 68%, P=0.022; 5-year overall survival (OS), ERG-deletion-positive 97% vs. ERG-deletion-negative 75%, P=0.029]. Ultra-deep amplicon-sequencing revealed distinct co-existing ERG-deletions in 22 of 24 patients. In conclusion, our data demonstrate inadequate sensitivity of single-nucleotide-polymorphism array for ERG-deletion detection, unacceptable for proper IKZF1plus classification. Even using more sensitive methods (PCR/amplicon-sequencing) for its detection, ERG-deletion is absent in 22-34% of DUX4-rearranged leukemia and does not represent an adequately sensitive marker of this leukemia subtype. Importantly, the ERG-deletion potentially stratifies the DUX4-rearranged leukemia into biologically/clinically distinct subsets. Frequent polyclonal pattern of ERG-deletions shows that late origin of this lesion is more common than has been previously described.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023849
003      
CZ-PrNML
005      
20201214131424.0
007      
ta
008      
201125s2019 it f 000 0|eng||
009      
AR
024    7_
$a 10.3324/haematol.2018.204487 $2 doi
035    __
$a (PubMed)30630977
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Zaliova, Marketa $u CLIP - Childhood Leukaemia Investigation Prague marketa.zaliova@lfmotol.cuni.cz. Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague. University Hospital Motol, Prague, Czech Republic.
245    10
$a ERG deletions in childhood acute lymphoblastic leukemia with DUX4 rearrangements are mostly polyclonal, prognostically relevant and their detection rate strongly depends on screening method sensitivity / $c M. Zaliova, E. Potuckova, L. Hovorkova, A. Musilova, L. Winkowska, K. Fiser, J. Stuchly, E. Mejstrikova, J. Starkova, J. Zuna, J. Stary, J. Trka,
520    9_
$a ERG-deletions occur recurrently in acute lymphoblastic leukemia, especially in the DUX4-rearranged subtype. The ERG-deletion was shown to positively impact prognosis of patients with IKZF1-deletion and its presence precludes assignment into IKZF1plus group, a novel high-risk category on AIEOP-BFM ALL trials. We analyzed the impact of different methods on ERG-deletion detection rate, evaluated ERG-deletion as a potential marker for DUX4-rearranged leukemia, studied its associations with molecular and clinical characteristics within this leukemia subtype, and analyzed its clonality. Using single-nucleotide-polymorphism array, genomic polymerase chain reaction (PCR) and amplicon-sequencing we found ERG-deletion in 34% (16 of 47), 66% (33 of 50) and 78% (39 of 50) of DUX4-rearranged leukemia, respectively. False negativity of ERG-deletion by single-nucleotide-polymorphism array caused IKZF1plus misclassification in 5 patients. No ERG-deletion was found outside the DUX4-rearranged cases. Within DUX4-rearranged leukemia, the ERG-deletion was associated with higher total number of copy-number aberrations, and, importantly, the ERG-deletion positivity by PCR was associated with better outcome [5-year event-free survival (EFS), ERG-deletion-positive 93% vs. ERG-deletion-negative 68%, P=0.022; 5-year overall survival (OS), ERG-deletion-positive 97% vs. ERG-deletion-negative 75%, P=0.029]. Ultra-deep amplicon-sequencing revealed distinct co-existing ERG-deletions in 22 of 24 patients. In conclusion, our data demonstrate inadequate sensitivity of single-nucleotide-polymorphism array for ERG-deletion detection, unacceptable for proper IKZF1plus classification. Even using more sensitive methods (PCR/amplicon-sequencing) for its detection, ERG-deletion is absent in 22-34% of DUX4-rearranged leukemia and does not represent an adequately sensitive marker of this leukemia subtype. Importantly, the ERG-deletion potentially stratifies the DUX4-rearranged leukemia into biologically/clinically distinct subsets. Frequent polyclonal pattern of ERG-deletions shows that late origin of this lesion is more common than has been previously described.
650    _2
$a mladiství $7 D000293
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    12
$a delece genu $7 D017353
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    12
$a genová přestavba $7 D015321
650    _2
$a homeodoménové proteiny $x genetika $7 D018398
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a pre-B-buněčná leukemie $x klasifikace $x diagnóza $x genetika $7 D015452
650    _2
$a prognóza $7 D011379
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a míra přežití $7 D015996
650    _2
$a transkripční regulátor ERG $x genetika $7 D000071230
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Potuckova, Eliska $u CLIP - Childhood Leukaemia Investigation Prague. Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague.
700    1_
$a Hovorkova, Lenka $u CLIP - Childhood Leukaemia Investigation Prague. Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague.
700    1_
$a Musilova, Alena $u CLIP - Childhood Leukaemia Investigation Prague. Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague.
700    1_
$a Winkowska, Lucie $u CLIP - Childhood Leukaemia Investigation Prague. Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague.
700    1_
$a Fiser, Karel $u CLIP - Childhood Leukaemia Investigation Prague. Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague.
700    1_
$a Stuchly, Jan $u CLIP - Childhood Leukaemia Investigation Prague. Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague.
700    1_
$a Mejstrikova, Ester $u CLIP - Childhood Leukaemia Investigation Prague. Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague. University Hospital Motol, Prague, Czech Republic.
700    1_
$a Starkova, Julia $u CLIP - Childhood Leukaemia Investigation Prague. Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague.
700    1_
$a Zuna, Jan $u CLIP - Childhood Leukaemia Investigation Prague. Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague. University Hospital Motol, Prague, Czech Republic.
700    1_
$a Stary, Jan $u Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague. University Hospital Motol, Prague, Czech Republic.
700    1_
$a Trka, Jan $u CLIP - Childhood Leukaemia Investigation Prague. Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague. University Hospital Motol, Prague, Czech Republic.
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 104, č. 7 (2019), s. 1407-1416
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30630977 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214131422 $b ABA008
999    __
$a ok $b bmc $g 1596168 $s 1114525
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 104 $c 7 $d 1407-1416 $e 20190110 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
GRA    __
$a NV15-30626A $p MZ0
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...